Endothelial Cell Activation and Total Pulmonary Resistance in PAH
ConditionPulmonary Artery Hypertension
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorImperial College London
About this trial
To determine whether changes in endothelial cell dysfunction are associated with changes in total pulmonary resistance in patients with pulmonary arterial hypertension
Eligibility criteria
Qualifiers
Subjects aged between 18-75 years old
PAH which is: idiopathic; PAH heritable; PAH associated with connective tissue disease; PAH after ≥ 1 year repair of congenital systemic to pulmonary shunt; or PAH associated with anorexignes or other drugs.
Resting mean pulmonary artery pressure ≥25 mmHg, pulmonary capillary wedge pressure ≤15 mmHg, PVR >5 wood units, and normal or reduced cardiac output, as measured by a previous right heart catheterisation (RHC).
Have an insertable FDA/CE cardiac rhythm monitor and pulmonary artery pressure monitor that captures cardiopulmonary haemodynamics and daily activity.
Disqualifiers
Unable to provide informed consent and/or are non-fluent speakers of the English language
Hypersensitivity to XBD173 or to any of the excipients
Clinically-significant renal disease (confirmed by creatinine clearance <30 ml/min per 1.73m2)
Clinically-significant liver disease (confirmed by serum transaminases >2 times than upper normal limit)
Trial design
Treatments tested in this trial
- XBD173
Treatment groups
6 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov